How a Cellular Modification Fuels Cancer Survival
In the intricate world of cellular biology, a discovery is rewriting the rules of cancer's playbook, revealing how a common cellular process can be hijacked to keep cancer cells alive.
Explore the DiscoveryImagine a factory where the workers who assemble proteins suddenly start protecting the factory from shutting down. This is similar to the surprising double life of certain ribosomal proteins in cancer cells. Recent research reveals that these multi-tasking molecules, when modified by a process called neddylation, become powerful protectors of cancer cells, offering a promising new avenue for therapeutic intervention.
Ribosomal proteins RPS27 and RPS27L, when modified by neddylation, act as pro-survival factors that protect cancer cells from apoptosis.
This article delves into the fascinating science behind this discovery, focusing on the pivotal experiment that uncovered the role of neddylation in breast cancer cell survival.
To appreciate this discovery, we first need to understand the key players.
Neddylation is a post-translational modification—a process that alters proteins after they are built, fine-tuning their function, location, and stability. It works by attaching a small protein called NEDD8 to target proteins. Think of it as adding a specific tag that can change how a protein behaves.
This process is essential for life, influencing everything from neuronal development to immune cell function 3 5 . However, in cancer, the neddylation pathway often becomes overactive, promoting the stability of proteins that drive tumor growth and survival 8 9 .
Ribosomes, the cell's protein synthesis factories, are built from ribosomal proteins (RPs). For decades, these proteins were thought to have a single, structural job. We now know that many RPs have a "double life." When not part of a ribosome, they can perform extra-ribosomal functions, such as regulating cell death and acting as tumor suppressors or promoters 6 .
Two such proteins are RPS27 and its close relative, RPS27L:
What happens when these two powerful cellular phenomena—neddylation and the extra-ribosomal functions of RPs—intersect?
A groundbreaking 2020 study published in the FASEB Journal sought to answer this question, focusing on the neddylation of RPS27 and RPS27L and its direct impact on cancer cell survival 1 .
Researchers designed a series of elegant experiments to unravel this relationship:
Confirmed neddylation of RPS27/RPS27L and identified MDM2 as E3 ligase and NEDP1 as deneddylase 1 .
Tracked protein half-lives after neddylation inhibition.
Used genetic approaches (knockdown/overexpression) to test effects on apoptosis 1 .
The findings were clear and compelling, forming a coherent story of how cancer cells exploit this pathway.
Blocking neddylation with MLN4924 dramatically shortened the protein half-lives of both RPS27 and RPS27L, showing that the NEDD8 tag acts as a stability signal, preventing these proteins from being degraded 1 .
Knocking down RPS27 or RPS27L made cancer cells more sensitive to MLN4924-induced apoptosis. Conversely, overexpressing the proteins made the cells more resistant to the drug 1 . This shows that stable, neddylated RPS27 and RPS27L act as pro-survival factors.
| Experimental Manipulation | Effect on Neddylation | Effect on RPS27/RPS27L Stability | Effect on Cancer Cell Apoptosis |
|---|---|---|---|
| Inhibit NAE with MLN4924 | Blocked | Decreased | Increased |
| Knockdown of RPS27/RPS27L | Not Directly Applied | Decreased | Increased (sensitized to MLN4924) |
| Overexpression of RPS27/RPS27L | Not Directly Applied | Increased | Decreased (resistant to MLN4924) |
In essence, the experiment demonstrated that neddylation is not just a passive marker on RPS27 and RPS27L; it is an active survival mechanism for cancer cells. By stabilizing these ribosomal proteins, the neddylation pathway helps tip the balance away from cell death.
To conduct such detailed research, scientists rely on a suite of specialized tools and reagents. The table below lists some of the essential components used in this field, many of which were pivotal in the featured study.
| Tool/Reagent | Function in Research | Specific Example/Use Case |
|---|---|---|
| MLN4924 (Pevonedistat) | A first-in-class NAE inhibitor; blocks all neddylation to study the pathway's function. | Used to destabilize RPS27/RPS27L and trigger cancer cell death 1 9 . |
| CRISPR/Cas9 Gene Editing | Allows precise deletion ("knockout") of genes of interest in cells or model organisms. | Used to generate NEDD8 knockout mice to study neddylation's role in neuronal development 3 . |
| Lentiviral Vectors | Engineered viruses used to deliver genetic material into cells to increase (overexpress) or decrease (knockdown) gene expression. | Used to create stable cell lines with RPS27 knockdown or overexpression for functional tests 1 4 . |
| Conditional Knockout Mice | Genetically engineered mice that allow gene deletion in specific tissues or at specific times. | The NEDD8 cKO mouse line allowed study of neddylation's role in post-mitotic neurons without embryonic lethality 3 . |
| UBE2M/UBE2F Inhibitors | Molecules that target the E2 conjugating enzymes of the neddylation pathway, offering more specific inhibition. | Emerging therapeutic strategy to disrupt neddylation of specific substrate subsets 9 . |
The implications of this RPS27/RPS27L neddylation mechanism extend far beyond breast cancer. Evidence is mounting that this is a common tactic used by various cancers:
A 2024 study found that a high-fat diet promotes prostate cancer metastasis by elevating RPS27 levels, which in turn activates genes involved in tumor progression 4 .
Neddylation-related genes are strong predictors of outcomes in melanoma, and neddylation pathways are considered promising therapeutic targets 8 .
By stabilizing ribosomal proteins, cancer cells may ensure not only efficient protein synthesis but also gain a surplus of these multi-functional proteins that can be deployed to block death signals.
The discovery that neddylation stabilizes RPS27 and RPS27L to promote cancer cell survival is more than an incremental advance. It reveals a novel vulnerability within cancer cells. The pivotal experiment, using MLN4924 to disrupt this process and trigger cell death, provides a powerful proof-of-concept for targeting this pathway therapeutically.
While challenges remain—including developing drugs that are more specific and understanding potential side effects—the research opens a promising front in the fight against cancer.
By understanding the double life of ribosomal proteins and the tag that controls them, scientists are one step closer to turning cancer's own survival mechanisms into its Achilles' heel.
References will be added here in the appropriate format.